JPL Wealth Management’s Syndax Pharmaceuticals SNDX Stock Holding History

JPL Wealth Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$117	Buy	+5	New	+$109	﹤0.01%	1455

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

JPL Wealth Management's SNDX Position: Q1 2026 in Review

JPL Wealth Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2026: 5 shares worth $117. The stake represents ﹤0.01% of the portfolio and ranks #1455 among its holdings.

246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

JPL Wealth Management held 5 shares of Syndax Pharmaceuticals worth $117 as of Q1 2026.
Syndax Pharmaceuticals was a new JPL Wealth Management position in Q1 2026.
Syndax Pharmaceuticals made up ﹤0.01% of JPL Wealth Management's portfolio in Q1 2026, its #1455 holding.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on JPL Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.